Exabis Library
Welcome to the e-CCO Library!
DOP47: Gut microbiome contributes to the development of immune checkpoint inhibitor-related colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP47: Identification and characterization of T-cell receptor sequences associated with Crohn’s Disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP47: Real World Evidence on the effectiveness of ustekinumab in Crohn’s Disease: Induction phase results from the prospective, observational RUN-CD Study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP47: Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP48 Gene expression landscape of epithelial monolayer in inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP48: Amiselimod, a selective S1P receptor modulator in Crohn’s disease patients: a proof-of-concept study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP48: Hedgehog signalling controls Th17 differentiation to drive intestinal inflammation and is a druggable target for the treatment of IBD
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP48: Key Anti-Inflammatory Faecalibacterium prausnitzii is Heterogeneous and Diverse in the East and West and in Health and Crohn's disease. The ENIGMA study.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP48: Use of biologic therapies with different mechanisms of action (MOA) in the first-line (1L) treatment of Crohn’s Disease (CD) in the U.S.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP49 Quantitative proteomics analysis of macrophages from Crohn’s disease patients and infected with adherent-invasive Escherichia coli
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP49: Context-dependent roles of High-mobility group box 1 (HMGB1) during intestinal inflammation and carcinogenesis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP49: Effectiveness and safety of vedolizumab in a matched cohort of elderly and young Inflammatory Bowel Disease patients - LIVE Study-Group
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP49: Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT II
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP49: Metagenomic Characterisation of The Colonic Mucosa-Associated Microbiota Reveals Novel Microbes and Communities in Health and Crohn's disease. The ENIGMA study.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP50 The landscape of somatic mutations in non-neoplastic IBD-affected colon
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP50: Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn’s disease: data from the CELEST study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP50: Impact of Inflammatory Bowel Disease associated dysbiosis on bacterial quorum sensing mediated by Acyl-homoserine Lactone in human gut microbiota
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP50: Oral α4β7 integrin inhibitor MORF-057 demonstrates exposure driven biomarker response in non-human primates
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP50: Recommencement of Inflammatory Bowel Disease medications following colectomy for Ulcerative Colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP51 Investigation on the role of Par4-associated cell polarity and associated barrier defects in inflammatory bowel diseases
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM